The End­points 11: They've got mad mon­ey and huge am­bi­tions. It's time to go big or go home

These days, se­lect­ing a group of pri­vate biotechs for the End­points 11 spot­light be­gins with a sprint to get ahead of IPOs and the M&A teams at Big Phar­ma. I’ve had a cou­ple of face­plants ear­li­er this year, watch­ing some of the biotechs on my short list choose a quick leap on­to Nas­daq or in­to the arms of a buy­er.

Vi­vid­ion, you would have been a great pick for the End­points 11. I’m sor­ry I missed you.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER